JP2023537396A - Ｉｌｔ２に対する抗体およびその使用 - Google Patents

Ｉｌｔ２に対する抗体およびその使用 Download PDF

Info

Publication number
JP2023537396A
JP2023537396A JP2023509679A JP2023509679A JP2023537396A JP 2023537396 A JP2023537396 A JP 2023537396A JP 2023509679 A JP2023509679 A JP 2023509679A JP 2023509679 A JP2023509679 A JP 2023509679A JP 2023537396 A JP2023537396 A JP 2023537396A
Authority
JP
Japan
Prior art keywords
antibody
seq
ilt2
antigen
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023509679A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023537396A5 (https=
JPWO2022034524A5 (https=
Inventor
イラーナ・マンデル
ツリ・ペレッツ
ダナ・ハヴェス・ジヴ
イラーナ・ゴールドシュタイン
ドロール・アリシェケヴィッツ
アンナ・フリードマン－ドロール
モッティ・ハキム
アヴィドール・シュルマン
ヤイル・サピア
テヒラ・ベン－モーシェ
Original Assignee
ビオンド バイオロジクス リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IL2020/050889 external-priority patent/WO2021028921A1/en
Application filed by ビオンド バイオロジクス リミテッド filed Critical ビオンド バイオロジクス リミテッド
Publication of JP2023537396A publication Critical patent/JP2023537396A/ja
Publication of JP2023537396A5 publication Critical patent/JP2023537396A5/ja
Publication of JPWO2022034524A5 publication Critical patent/JPWO2022034524A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2023509679A 2020-08-12 2021-08-11 Ｉｌｔ２に対する抗体およびその使用 Pending JP2023537396A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
PCT/IL2020/050889 WO2021028921A1 (en) 2019-08-12 2020-08-12 Antibodies against ilt2 and use thereof
ILPCT/IL2020/050889 2020-08-12
US202163145604P 2021-02-04 2021-02-04
US63/145,604 2021-02-04
US202163149371P 2021-02-15 2021-02-15
US63/149,371 2021-02-15
PCT/IB2021/057414 WO2022034524A2 (en) 2020-08-12 2021-08-11 Antibodies against ilt2 and use thereof

Publications (3)

Publication Number Publication Date
JP2023537396A true JP2023537396A (ja) 2023-08-31
JP2023537396A5 JP2023537396A5 (https=) 2024-08-20
JPWO2022034524A5 JPWO2022034524A5 (https=) 2024-08-20

Family

ID=80223922

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023509679A Pending JP2023537396A (ja) 2020-08-12 2021-08-11 Ｉｌｔ２に対する抗体およびその使用

Country Status (14)

Country Link
US (1) US12071479B2 (https=)
EP (1) EP4196227A2 (https=)
JP (1) JP2023537396A (https=)
KR (1) KR20230058074A (https=)
CN (1) CN116096756A (https=)
AU (1) AU2021325430A1 (https=)
BR (1) BR112023002301A2 (https=)
CA (1) CA3190634A1 (https=)
CO (1) CO2023002375A2 (https=)
IL (1) IL300588A (https=)
MX (1) MX2023001776A (https=)
TW (1) TW202221035A (https=)
WO (1) WO2022034524A2 (https=)
ZA (1) ZA202302392B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022001841A (es) 2019-08-12 2022-08-17 Biond Biologics Ltd Anticuerpos contra ilt2 y uso de los mismos.
US20250197491A1 (en) * 2022-03-11 2025-06-19 Macomics Limited Compositions and methods for modulation of macrophage activity
CN116082500B (zh) * 2022-12-09 2023-08-22 珠海重链生物科技有限公司 抗SARS-CoV-2抗体nCoV1和nCoV2及其应用
WO2024207855A1 (zh) * 2023-04-04 2024-10-10 成都优洛生物科技有限公司 抗lilrb1抗体或其抗原结合片段、制备方法和用途
US20250019441A1 (en) 2023-07-11 2025-01-16 Biond Biologics Ltd. Treatment of cancer with anti-ilt2 antibodies
TW202525855A (zh) * 2023-08-31 2025-07-01 美商艾克塞里克斯公司 Ｉｌｔ２結合劑及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020006347A1 (en) * 2018-06-29 2020-01-02 Boehringer Ingelheim International Gmbh Anti-cd40 antibodies for use in treating autoimmune disease
WO2020136147A1 (en) * 2018-12-26 2020-07-02 Innate Pharma Compounds and methods for treatment of head and neck cancer

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5719867A (en) 1995-06-30 1998-02-17 Scientific-Atlanta, Inc. Plural telephony channel baseband signal demodulator for a broadband communications system
US7803376B2 (en) 2003-07-24 2010-09-28 Innate Pharma S.A. Methods and compositions for increasing the efficiency of therapeutic antibodies using NK cell potentiating compounds
EP3209769B1 (en) 2014-10-24 2020-08-05 The Board of Trustees of the Leland Stanford Junior University Compositions and methods for inducing phagocytosis of mhc class i positive cells and countering anti-cd47/sirpa resistance
CA3012055A1 (en) 2016-01-21 2017-07-27 Innate Pharma Neutralization of inhibitory pathways in lymphocytes
TW201829463A (zh) 2016-11-18 2018-08-16 瑞士商赫孚孟拉羅股份公司 抗hla-g抗體及其用途
TWI796329B (zh) 2017-04-07 2023-03-21 美商默沙東有限責任公司 抗－ilt4抗體及抗原結合片段
EP3740224A4 (en) * 2018-01-18 2022-05-04 Adanate, Inc. ANTI-LILRB ANTIBODIES AND THEIR USES
US20210301020A1 (en) 2018-07-24 2021-09-30 Amgen Inc. Combination of lilrb1/2 pathway inhibitors and pd-1 pathway inhibitors
MX2022001841A (es) 2019-08-12 2022-08-17 Biond Biologics Ltd Anticuerpos contra ilt2 y uso de los mismos.
EP4045535A1 (en) 2019-10-14 2022-08-24 Innate Pharma Treatment of cancer with ilt-2 inhibitors
WO2021133036A1 (ko) 2019-12-23 2021-07-01 주식회사 엘지화학 항-lilrb1 항체 및 그의 용도
AU2021265801B2 (en) 2020-05-01 2026-04-02 Ngm Biopharmaceuticals, Inc. ILT-binding agents and methods of use thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020006347A1 (en) * 2018-06-29 2020-01-02 Boehringer Ingelheim International Gmbh Anti-cd40 antibodies for use in treating autoimmune disease
WO2020136147A1 (en) * 2018-12-26 2020-07-02 Innate Pharma Compounds and methods for treatment of head and neck cancer
WO2020136145A2 (en) * 2018-12-26 2020-07-02 Innate Pharma Leucocyte immunoglobulin-like receptor neutralizing antibodies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J. IMMUNOL., vol. 203, no. 12, JPN7025003179, 2019, pages 3386 - 3394, ISSN: 0005774976 *

Also Published As

Publication number Publication date
WO2022034524A3 (en) 2022-04-28
KR20230058074A (ko) 2023-05-02
IL300588A (en) 2023-04-01
EP4196227A2 (en) 2023-06-21
TW202221035A (zh) 2022-06-01
US20220048991A1 (en) 2022-02-17
ZA202302392B (en) 2025-05-28
CN116096756A (zh) 2023-05-09
AU2021325430A1 (en) 2023-04-20
MX2023001776A (es) 2023-03-10
CO2023002375A2 (es) 2023-03-27
BR112023002301A2 (pt) 2023-10-03
US12071479B2 (en) 2024-08-27
WO2022034524A2 (en) 2022-02-17
CA3190634A1 (en) 2022-02-17

Similar Documents

Publication Publication Date Title
KR102433076B1 (ko) Ilt2에 대한 항체 및 이의 용도
JP7844425B2 (ja) 抗ｔｇｆベータ抗体およびそれらの使用
US12071479B2 (en) Antibodies against ILT2 and use thereof
TWI873311B (zh) Ｐｖｒｉｇ結合蛋白及其醫藥用途
CN106573977B (zh) 针对ceacam1的人源化抗体
SA518390834B1 (ar) توليفة جديدة للاستخدام في علاج السرطان
US20250051464A1 (en) Epha2 antibodies
JP2022553927A (ja) Ｉｌｔ－２阻害剤での癌の処置
EP4731256A1 (en) Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer
JP2025513588A (ja) 抗ｉｌｔ３抗体およびその使用
US20250215087A1 (en) Combination therapy of kras inhibitor and treg depleting agent
US20220025034A1 (en) Methods of treating immunotherapy-related toxicity using a gm-csf antagonist
RU2832673C2 (ru) Антитела, направленные против ilt2, и их применение
CN116199777B (zh) 抗hNKG2D抗体及其应用
WO2025062392A1 (en) Anti-ilt3 blockade combinations
JP2024514255A (ja) 増強された抗ｈｖｅｍ抗体及びその使用
HK40117648A (zh) Il-18bp拮抗剂抗体及其在癌症治疗中的单一疗法和组合疗法中的用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240809

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240809

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250711

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250715

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251003

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260120